Five days after the Department of Justice formally rescheduled state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, the Drug Enforcement Administration moved quickly to operationalize the change. On April 28, the agency published a cluster of notices in the Federal Register laying out licensing requirements, withdrawing its original 2024 rescheduling proposal, and setting a firm timeline for the long-deferred public hearing on whether non-medical marijuana should stay in Schedule I. The machinery, after years of stalls, is now visibly turning.
The Hearing That Wouldn't Die - Now Has a Date
The administrative hearing on non-medical marijuana's Schedule I status is slated to begin June 29 and conclude by July 15. Parties wishing to participate must file a request with the DEA by May 28; the agency will notify selected participants on June 22. Acting Attorney General Todd Blanche will designate the administrative law judge to preside, though no appointment has been announced.
This hearing was originally scheduled for January 2025. DEA Administrative Law Judge John Mulrooney postponed it, and the proceeding sat in bureaucratic limbo until the April 23 DOJ announcement broke the logjam. The DEA's April 28 withdrawal of its original May 2024 rescheduling notice is a procedural reset - the agency stated it determined that terminating the old hearing proceedings and initiating new ones was "the most expeditious manner of completing the rulemaking process in accordance with Federal law." That sounds tidy on paper, but it reflects the underlying complexity: rescheduling marijuana involves not just domestic law but binding international treaty obligations, and threading that needle has repeatedly tripped up the federal apparatus.
What Dispensaries Now Have to Do - and Fast
Here's where the rubber meets the road for the cannabis industry. Any entity seeking to handle FDA-approved medical marijuana products must register with the DEA and obtain a Schedule III controlled substance license. A new registration portal opened April 29 at 9 a.m. EST. State-licensed medical dispensaries can apply using their existing state credentials - a meaningful concession that avoids forcing operators to rebuild their compliance documentation from scratch.
The registration fee is $794 annually. The only accepted payment method at launch is PayPal, which the DEA acknowledged is limited, stating it plans to add options "in the coming weeks." For an industry accustomed to operating largely in cash due to federal banking restrictions, the irony of a PayPal-only portal is not lost. Still, the mechanics of the registration system reflect a broader structural logic: the DEA has determined that folding state-level licensing into its existing federal registration framework is "the most effective and efficient" path to reconciling the rescheduling with both domestic and international law.
The U.N. Treaty Problem - and a Workaround
The United Nations Single Convention on Narcotic Drugs, to which the United States is a signatory, has long required that a government agency serve as the exclusive purchaser of cannabis designated for Schedule I research purposes. Schedule III doesn't carry the same constraint for medicinal use - but, out of caution, the DEA is establishing a "purchase-and-resale mechanism." Under this arrangement, the agency will buy marijuana crops from registered manufacturers and immediately resell them back at the same price. A pass-through transaction, functionally a formality, designed to keep the U.S. in treaty compliance without actually concentrating supply in federal hands.
The agency also addressed a specific liability gap for researchers. The notice explicitly states that scientists who obtain marijuana or marijuana-derived products from a state-licensed source - rather than a separately DEA-registered bulk manufacturer - will face no civil or criminal liability under the Controlled Substances Act solely for having done so. The DEA's administrator will not treat such sourcing as grounds for adverse action. This is a meaningful protection. Research into cannabis has been severely constrained for decades in part because the only federally sanctioned supply came from a single DEA-licensed cultivator; loosening the sourcing requirement, even informally, could open pathways for broader scientific inquiry.
What Comes Next, and What's Still Unresolved
The June-July hearing will focus specifically on non-medical marijuana - meaning the outcome could produce a split classification: Schedule III for medical, Schedule I for recreational and unclassified use. That bifurcation, if it holds, would create a regulatory structure without a clean precedent in American drug policy. Dispensaries operating in states with adult-use markets would face a patchwork of federal obligations depending on what portion of their inventory is deemed "medical."
The longer downstream effect may be on research. If federal researchers can now source cannabis from state-licensed operators, the volume and variety of material available for clinical study expands substantially. That doesn't resolve every barrier - federal funding restrictions, institutional risk aversion, and the still-contested scheduling of the plant itself all remain - but it removes one significant procedural wall. Whether that translates into meaningful research acceleration depends on what the June hearing produces, and on how aggressively the scientific community moves to apply.
